CANNABIS POLAND S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.706 PLN | +3.82% |
|
+1.29% | +112.01% |
| 05-15 | Cannabis Poland S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-14 | Cannabis Poland S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2022 | 200K 49.55K 3.92M | Sales 2023 | 54.57K 13.52K 1.07M | Capitalization | 11.58M 2.87M 227M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -1M -248K -19.58M | EV / Sales 2022 | 49.5 x |
| Net cash position 2022 | 263K 65.17K 5.15M | Net cash position 2023 | 1.12M 278K 22M | EV / Sales 2023 | 192 x |
| P/E ratio 2022 |
-15
x | P/E ratio 2023 |
-10
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.82% | ||
| 1 week | +1.29% | ||
| Current month | +5.85% | ||
| 1 month | -1.81% | ||
| 3 months | +27.44% | ||
| 6 months | +109.50% | ||
| Current year | +112.01% |
1 week
0.65
0.74
1 month
0.650.74
Current year
0.301.04
1 year
0.281.04
3 years
0.182.84
5 years
0.184.29
10 years
0.184.29
| Managers | Title | Age | Since |
|---|---|---|---|
| Corporate Officer/Principal | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 31/10/22 | |
| Corporate Officer/Principal | 52 | - | |
| Chairman | 53 | 31/12/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 0.706 | +3.82% | 1,489,052 |
| 19/06/24 | 0.68 | -1.31% | 65,193 |
| 18/06/24 | 0.689 | +2.53% | 132,738 |
| 17/06/24 | 0.672 | -1.90% | 112,977 |
| 14/06/24 | 0.685 | -1.72% | 47,593 |
End-of-day quote Warsaw S.E., June 19, 2024
More quotes
Cannabis Poland SA, formerly Telehorse SA, is a Poland-based company engaged in the Pharmaceutical and Medicine Manufacturing activity. The Company focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The Company also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The Company is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +112.01% | 8.6M | |
| +81.46% | 1.7B | |
| +84.13% | 62.17M |
- Stock Market
- Equities
- CBD Stock
